Two injections, two different jobs

Patients comparing these two treatments often ask which is better — but that framing assumes they compete for the same role. They do not. ChondroFiller® and Arthrosamid® address anatomically separate parts of the same joint, which is why the clinically useful question is not which one wins but which problem is actually present.

ChondroFiller® (Meidrix Biomedicals, Germany) is an injectable type I/III collagen scaffold placed under ultrasound guidance directly onto the articular cartilage surface — the load-bearing tissue at the ends of the bones. Once in place, it sets within minutes and acts as an acellular matrix that recruits the patient's own progenitor cells, supporting the body's endogenous repair processes at a focal cartilage defect over a period of six to twelve months.

Arthrosamid® is a different proposition entirely. This permanent polyacrylamide hydrogel (2.5% polyacrylamide, 97.5% water) integrates into the synovial lining — the membrane that encloses the joint — rather than the cartilage surface. Its action is mechanical cushioning and modulation of synovitis-driven pain. It does not restore cartilage tissue.

Both are delivered as outpatient, ultrasound-guided injections — neither constitutes surgery. Where an individual presents with a focal cartilage defect and significant synovitis, a clinician might assess whether each has a separate anatomical justification; the two should never be treated as interchangeable fillers acting through the same mechanism.

Patients most likely to be assessed for ChondroFiller

The clearest clinical signal pointing towards ChondroFiller® is a focal cartilage defect — localised damage at a load-bearing articular surface, typically confirmed on MRI or arthroscopic assessment, rather than the diffuse, joint-wide wear of end-stage arthritis. The pain pattern often matches: mechanical discomfort under load, activity-related swelling, and a joint that has not responded fully to physiotherapy or conservative measures.

Age is not a barrier. The injectable scaffold pathway carries no upper age ceiling, and some degree of bone-on-bone change elsewhere in the joint does not automatically rule a patient out. What the specialist is weighing is whether the defect is contained and the surrounding tissue viable — not the patient's birth year.

Two factors do exclude patients outright: poorly controlled diabetes and immunosuppression, both of which impair the cell-recruitment process the scaffold relies on. Where disease is very advanced — involving large, unstable defects across a substantial portion of the articular surface — clinical assessment may indicate that the injectable pathway alone is insufficient and a more involved treatment approach is better suited.

Published outcome data provide some structural reference points. In knee series, IKDC scores have shown approximately 30-point improvements, and MOCART imaging scores in the 70–87 range reflect measurable structural change over six to twelve months — evidence of the scaffold doing its intended biological work rather than simply masking symptoms.

Patients most likely to benefit from Arthrosamid

The evidence base for Arthrosamid® rests on observational cohort data rather than randomised controlled trials — a distinction worth holding in mind when interpreting the published findings.

The largest dataset followed 314 knees across 269 patients over 24 months. Four factors independently predicted a clinically meaningful improvement in patient-reported outcomes: older age, lower Kellgren–Lawrence (KL) grade, non-diabetic status, and bilateral rather than unilateral OA. These are the variables specialists tend to probe at assessment — not as guarantees of a positive result, but as indicators of who the existing evidence suggests is most likely to respond.

The KL grade finding carries particular practical weight. Patients at grade II or III, where synovitis-driven pain is a prominent complaint and structural deterioration has not yet become extensive, showed the most consistent benefit. Those at KL grade IV were significantly more likely to progress to total knee replacement within two years, pointing to Arthrosamid® as an intermediate-stage intervention rather than a late-stage alternative to surgery.

Diabetes emerged as a negative predictor in this cohort — consistent with the contraindication patterns associated with other injectable therapies, including ChondroFiller®. The mechanism behind this interaction has not been fully characterised in the available data.

One further consideration for suitable candidates: Arthrosamid® is a permanent implant. For patients who respond well, that durability removes the need for planned retreatment. It also makes a clear pre-injection conversation about what 'permanent' means in practice an important part of the consent process.

When both injections might be considered for the same knee

The anatomical logic — that these products address different structures within the same joint — is what makes combination use theoretically coherent rather than redundant. But coherence in principle is not the same as an established clinical pathway.

No published evidence base exists for using ChondroFiller® and Arthrosamid® together in the same knee. Where a specialist does consider both, each product would need to be justified entirely on its own terms: ChondroFiller® for a focal articular cartilage defect that meets its selection criteria, Arthrosamid® for synovial-membrane-driven pain that meets its own. The two rationales would need to stand independently — not reinforce each other in a circular way.

Combination use, where it arises, is therefore the outcome of two parallel assessments arriving at compatible conclusions, not a single additive decision. It is not a standard pathway, and it should not be read as suggesting the products are interchangeable, equivalent in mechanism, or that one amplifies the effect of the other.

What the evidence can and cannot tell you

Neither product has been tested against the other in a randomised controlled trial — a limitation of the field as a whole rather than a characteristic unique to either injection.

The Arthrosamid® evidence base is the more published of the two: the 24-month cohort of 314 knees provides the core outcome data, supplemented by a 12-month open-label study (Bliddal et al., J Orthop Surg Res, 2024). A retrospective comparison (n=150) found iPAAG superior to corticosteroid at six months and marginally better than hyaluronic acid at 12 months — though that durability advantage did not reach statistical significance (p=0.219). Without a randomised control group in the larger cohort, absolute effect sizes remain estimates rather than established figures.

For ChondroFiller®, the published evidence on the injectable scaffold pathway specifically is more limited; much of the existing clinical literature relates to arthroscopic delivery routes. That distinction matters: outcomes from surgical implantation studies do not automatically transfer to the outpatient injection setting.

One methodological note on safety data: some Arthrosamid® trial reporting used patient-reported 'sensation of distension' rather than imaging or clinical examination to identify joint effusion. The true incidence of inflammatory joint reaction may therefore be somewhat higher than published adverse-event rates suggest — worth raising in any pre-treatment risk conversation.

Taken together, a patient weighing ChondroFiller® is working from a mechanistically grounded but injection-specific evidence base that remains comparatively thin; one considering Arthrosamid® has broader cohort support but should treat published outcome figures as group-level observations — informative context for a decision, not an individual forecast.

Questions to ask when you see a specialist

Before a first consultation, having a focused set of questions makes the conversation more productive. The following are worth raising, depending on which option is being discussed:

• Does my scan or assessment suggest a focal cartilage defect, diffuse OA, or both? The answer directly shapes which injection — if either — is clinically appropriate, since the two products address distinct anatomical targets.
• What is my Kellgren-Lawrence grade, and how does that affect likely response? Published cohort data show KL grade is one of the stronger independent predictors of outcome, particularly for Arthrosamid®.
• If Arthrosamid® is being proposed, what does 'permanent implant' mean for my future options? The hydrogel integrates into the synovial lining and cannot be removed — relevant context for planning any subsequent treatment.
• If ChondroFiller® is being proposed, what is the expected timeline for improvement, and what imaging follow-up is planned? Scaffold-mediated repair unfolds over months rather than days.
• Search MSK lists specialists across the UK who offer cartilage injection therapies — filter by region and specialty to find one who can assess your specific situation.